MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.
AEYE Health is set to share the company’s FDA-cleared portable AI solution for autonomous diabetic retinopathy screening at several upcoming medical conferences in October. The device and the ...
A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over inadequate screening and management, especially among Black and Hispanic youths.
In a study, a team of UCLA investigators detail a deep-learning model pre-trained on 2D scans that accurately predicts disease-risk factors from 3D medical-scan modalities. Toku’s AI technology, CLAiR ...
According to research conducted by investigators at the Perelman School of Medicine at the University of Pennsylvania School of Medicine, patients with a rare inherited disease affecting their sight ...
This patented technology is designed to enhance the light sensitivity of a multi-characteristic opsin developed by Nanoscope as a gene therapy. Nanoscope Therapeutics Inc. has acquired a license for ...
It is not every day that a paper about treating eye disease appears in The Lancet. 1 The article by Campochiaro et al1 on a clinical trial of gene therapy speaks to the potential impact of this ...
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab At this year's EURETINA Congress, Timothy L Jackson PhD, MB ChB ...